Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8439285 | 0.95 | NCF1 (0.41) | ALDH1A1L3MBTL1L3MBTL3NCF1ALOX15 | |
| SCHEMBL18379027 | 0.95 | NCF1 (0.41) | ALDH1A1L3MBTL1L3MBTL3NCF1ALOX15 | |
| SCHEMBL24204613 | 0.90 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1L3MBTL3NCF1ALOX15 | |
| SCHEMBL26743364 | 0.90 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1L3MBTL3NCF1ALOX15 | |
| SCHEMBL26042916 | 0.89 | L3MBTL3 (0.47) | ALDH1A1L3MBTL1L3MBTL3NCF1ALOX15 | |
| SCHEMBL24480974 | 0.89 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1L3MBTL3NCF1ALOX15 | |
| SCHEMBL24480310 | 0.89 | ALDH1A1 (0.37) | ALDH1A1L3MBTL1L3MBTL3NCF1ALOX15 | |
| SCHEMBL15185049 | 0.87 | — | — | |
| SCHEMBL12772837 | 0.87 | L3MBTL3 (0.46) | ALDH1A1L3MBTL1L3MBTL3NCF1ALOX15 | |
| SCHEMBL3436969 | 0.87 | L3MBTL1 (0.46) | ALDH1A1L3MBTL1L3MBTL3NCF1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | ALDH1A1 3281/4885L3MBTL1 1119/4885L3MBTL3 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.